Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
A key pivotal study of bemarituzumab will read out shortly.
Recent phase 1 entrants include a ROR1 ADC and a mystery Kelun project.
The FDA will rule on a low dose of zongertinib in the summer.
US approval could mark the company's graduation to oncology.
A triplet did worse than control in first-line kidney cancer.
Meanwhile, Tango tries again in PRMT5.
